Patheon, the pharmaceutical services business unit of DPx Holdings B.V., is a global provider of development and commercial manufacturing services for prescription drugs. "With this Patheon agreement completed
Under the terms of the agreement, Sutro will provide its Xpress CF technology for the rapid and reproducible expression of antibodies and antigens by the Wells Lab for
"The astronomical rate of obesity is unfortunate, but as a business; it’s something ANAS can capitalize on. We can’t control the world’s eating and activity habits but that
The company’s drug targets the specific elimination of Streptococcus mutans, the acid producing bacterium associated with dental caries or tooth decay. C16G2 is the first peptide therapeutic derived
The newly issued patent claims cover compositions and methods for manufacturing vaccines utilizing ThermoVax, the Company’s proprietary vaccine thermostabilization technology. The new patent complements US patent 8,444,991, granted
"COTI-2 is selectively active in in vivo and in vitro models with abnormal TP53. This is very exciting as TP53 is one of the "big three" of critically
Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg.
Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.
The solution, Just-In-Time (JIT), addresses inefficiencies in the oncology drug-development process, which fails to match the increasing molecular stratification of cancers. The evaluation represents a key collaboration between
Last month, Par received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for dexmedetomidine HCl injection, which is indicated for sedation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.